Introduction
The development of relevant high-throughput screening technologies to assess safety of lead compounds at the early stages of drug discovery is extremely important for identifying safe lead chemicals and/or series. Since its discovery in the early 1970s by Ames et al. (1) , the Salmonella reverse mutation plate incorporation assay has been widely used to detect the mutagenic activity of drug candidates and environmental chemicals. The Salmonella assay, commonly referred to as the Ames assay, was validated by the testing of several hundred chemicals through a programme sponsored by the National Toxicology Program (NTP) (2) (3) (4) (5) (6) . Positive responses in the Salmonella reverse mutation assay have a good correlation with the outcome of rodent carcinogenicity testing (7, 8) . As the results of the Salmonella assay are required by regulatory agencies for drug approvals worldwide (9) , a positive Ames result in the Salmonella assay frequently stops development particularly if these compounds are intended for the treatment of non-life threatening diseases or disorders (10) .
In brief, the Salmonella reverse mutation assay detects reversions of auxotrophic mutations in Salmonella typhimurium, which either are base-pair substitution or frame shift mutations in histidine synthesis pathway genes. Such histidine-dependent cells are not capable of synthesizing endogenous histidine which results in no growth in histidinefree media. A reverse mutation that restores endogenous histidine biosynthesis enables bacterial growth even in the absence of exogenous histidine (histidine-independent cells). In the standard Ames assay, the treatment of histidinedependent cells with mutagens leads to an increased number of bacterial revertants (histidine-independent cells) detected as colonies over a background lawn of histidine-dependent cells.
Despite the relative simplicity of the standard Salmonella reverse mutation assay, its application as a screening tool in the early phases of drug discovery is not feasible due to a lack of high-throughput attributes. Several attempts to miniaturize the Ames assay, such as the Spiral assay, Miniscreen, Mutascreen, and Ames II assays, have been published (11) (12) (13) (14) (15) . Although Spiral and Miniscreen have been applied in drug discovery settings (16, 17) , their use is limited due to cumbersome methods to detect revertants, relatively high compound requirements, low throughput and low potential for automation.
We have recently reported the development of the bioluminescent reverse mutation assay in Salmonella as a higher throughput platform applicable for the screening of large sets of the compounds (18) . The bioluminescent Salmonella assay utilizes genetically engineered standard Ames Salmonella tester strains TA98 and TA100 expressing the lux (CDABE) operon from Xenorhabdus luminescens. The assay employs bioluminescence as a sensor of changes in bacterial metabolism associated with starvation effectively identifying colonies of histidine-dependent revertant cells. The bioluminescent Salmonella assay provides an economical, higher throughput tool for assessment of mutagenicity with high concordance to outcomes in the current Ames standard plate incorporation method (18) . In this study, we present an inter-laboratory evaluation of the bioluminescent Salmonella assay that consisted of the evaluation of 10 well-characterized model agents by five independent laboratories.
Materials and methods

Test chemicals
Ten model compounds were purchased (Sigma, St Louis, MO) and used in this inter-laboratory evaluation: 2-amino-5-nitrophenol (2A5N), CAS #121-88-0; anthracene (Anthra), CAS #120-12-7; benzyl chloride (BC), CAS #100-44-7; benzo[a]pyrene (BaP), CAS #50-32-8; 1,4-benzoquinone dioxime (14BQD), CAS #105-11-3; 2-bromo-4,6-dinitroaniline (2B46dNA), CAS #1817-73-8; busulfan (Bus), CAS #55-98-1; crystal violet (CV), CAS #548-62-9; 3-3#-dimethoxybenzidine (33DMB), CAS #119-90-4 and nitrofurazone (5N2F), CAS #59-87-0.
Bioluminescent Salmonella reverse mutation assay Procedures were described in detail by Aubrecht et al. (18) . Briefly, Salmonella cells were grown overnight at 37°C, under shaking (250 r.p.m.), in 35 ml of Luria-Bertani (LB) medium (Invitrogen/Difco, Grand Island, NY) which was supplemented with 50 lg/ml kanamycin (Sigma). The next morning, the culture was diluted 3:1 with fresh LB broth (with supplemented kanamycin) and incubated at 37°C for an hour. Cells were then centrifuged and washed twice in phosphate-buffered saline (PBS) (Sigma) and finally adjusted to Optical Density 660 5 0.5 in the final cell suspensions. For sterile top agar solution of 14.5 ml, the following components were prepared: 400 ll of 50Â VogelBonner salt concentrate (Northeast Laboratory, Waterville, ME), 880 ll of biotin (170 lg/ml), 20 ll of histidine (6.7 mg/ml), 20 ll of kanamycin (50 mg/ ml), 3.0 ml of glucose (2.6%), 5.2 ml of molten agar (2.4%), 5.0 ml of final adjusted cells (OD 660 5 0.5) and kept at 50°C. To minimize the exposure of Salmonella cells to a high temperature, the top agar mixture was used within 10 min after addition of cell suspension to the mix.
The assay was performed in 24-well minimal agar plates (1 ml per well) prepared either on-site or purchased (Molecular Toxicology, Boone, NC). The minimal agar was prepared using 15 g Bacto Agar (Difco, Franklin Lakes, NJ), 4 g glucose and 20 ml of 50Â Vogel-Bonner salt concentrate (1% MgSO 4 Â H 2 O, 10% citric acid, monohydrate, 50% K 2 HPO 4 , 17.5% Na 2 NH 2 PO 4 Â 4H 2 O) in total volume of 1000 ml of distilled water. Sterilized agar was tempered to 50°C in the water bath prior dispensing 1 ml per well. The assay procedure was to dispense 17.5 ll of PBS or 17.5 ll of completed S9 mixture of Aroclor-induced rat S9 liver homogenate onto the well per agar. The S9 homogenate was purchased from Molecular Toxicology for all testing laboratories except Nagoya (NAG), which used S9 from Charles River (Wilmington, MA). Then, either 10 ll of the compound solution or negative control was added onto the wells. Then 72 ll of the top agar containing cells was added. Each 24-well plate was agitated on a shaker at 950 r.p.m. to allow even distribution of cells on the surface. The range of final Salmonella cell density was $4 Â 10 6 to 3 Â 10 7 cells per well over the five laboratories. The standard doses of tested compounds were 3-fold serial dilutions starting at 5 mg per well or plate. The maximum concentration tested in the bioluminescent assay was 1.35 mg/ml in the final overlay, which translates to 0.135 mg per well which corresponds to 5 mg per plate in the standard Ames Salmonella assay. All concentrations in the bioluminescent assay were expressed as corresponding milligrams per plate equivalent to facilitate the comparison of Bioluminescent and plate assay data. The positive controls for TA100-lux and TA98-lux in the absence of metabolic activation were nitrofurantoin at 0.007 mg per plate eq. and 2-nitrofluorene at 0.018 mg per plate eq., respectively. The positive control in the presence of metabolic activation for strains TA100-lux and TA98-lux were 2-anthramine at 0.018 mg per plate eq. and 0.037 mg per plate eq., respectively. Plates were incubated at 37°C for 40-48 h and revertants of luminescent colonies were captured and scored by using photon counting CCD camera (Lumi-Imager F1, Roche, Palo Alto, CA). Inverted images of luminescent revertants of each 24-well per each plate were displayed. Numbers of revertants in negative controls for each strain and condition (i.e. direct or with metabolic activation) were pooled to obtain daily activity value (DAC). Averaged numbers of revertants using doses of test articles were compared to the DAC for respective strain and condition and were reported as fold increases.
Inter-laboratory evaluation study design The inter-laboratory evaluation involved five independent laboratories located in the USA [Groton (GTN), CT; Cambridge (CAM), MA and La Jolla (LJ), CA], Europe Sandwich (SDW), Kent, UK and Asia Nagoya (NAG) Japan. The compounds were coded and distributed from our Groton laboratory in a blinded fashion to LJ, CA; SDW, UK and NAG, Japan. The laboratory located in CAM, MA purchased all 10 compounds independently from the same vendor and their studies were not blinded. All 10 chemicals were tested in at least three independent experiments using strains TA98-lux and TA100-lux in the presence and absence of metabolic activation (rat S9). The results were statistically evaluated using the t-test and compared to each site and to published NTP results (2-6). Evaluation criteria for positive responses of the five inter-laboratory sites were dose dependent, statistically significant (P 0.05), !2.0-fold increase of revertant colonies over negative (untreated) controls. Evaluation criteria for positive responses of NTP were !2.0-fold increase of revertant colonies over negative (untreated) controls. All data were graphed using GraphPad Prism 4, v. 4.00 (GraphPad Software, Inc., San Diego, CA).
Results
We have performed an inter-laboratory evaluation of the bioluminescent Salmonella assay using 10 model chemicals in five independent laboratories located in the USA: GTN, CT, CAM, Individual values represent the average of incidence of revertants in solvent treated wells (negative controls) AE SD for individual strains and conditions. GTN, Groton CT; SDW, Sandwich, Kent, UK; LJ, La Jolla CA; NAG, Nagoya, Japan; CAM, Cambridge, MA. a TA98-lux and TA100-lux strains, tested directly (without rat S9) or with metabolic activation (plus S9). b Represents default value for background incidence of revertants in untreated wells with TA98-lux strain. Individual values represent average fold of increase of revertants in wells treated with positive reference compounds (positive control). GTN, Groton CT; SDW, Sandwich, Kent, UK; LJ, La Jolla CA; NAG, Nagoya, Japan; CAM, Cambridge, MA. 2-A, 2-anthramine; 2-Nit, 2-nitrofluorene; Nit, nitrofurantoin.
MA and LJ, CA; Europe: SDW, Kent, UK and Asia: NAG, Japan. The studies were performed in blinded fashion at all laboratories except for GTN and CAM. The chemicals were tested in at least three independent experiments using strains TA98-lux and TA100-lux in the presence and absence of metabolic activation (rat S9). The results were statistically evaluated according to the criteria described in Materials and Methods and compared to previously published Salmonella assay results (2-6).
The range of average background incidences of revertants is presented in Table I . In case of TA100-lux strain in the presence or absence of metabolic activation, the background ranged from 5.2 to 12.3 revertants per well across individual laboratories. The average background incidence of revertants for TA98-lux strain in the presence or absence of metabolic activation ranged from 0.5 to 2.3. Due to low background incidence of revertant colonies in the TA98-lux strain, we have used a default 1.5 revertants per well as the background for experiments that yielded ,1.5 revertants per well. The results in individual laboratories with positive control compounds are summarized in Table II . The treatment of TA98-lux cells with 2-anthramine in the presence of metabolic activation or 2-nitrofluorene in absence of metabolic activation resulted in 32.0-to 42.0-fold or 17.9-to 31.6-fold increase of revertant colonies, respectively. In case of TA100-lux, the treatment with 2-anthramine in the presence of metabolic activation and nitrofurantoin in absence of metabolic activation resulted in 7.1-to 13.1-fold increase or 3.3-to 8.2-fold induction of revertants, respectively.
The results of the bioluminescent Salmonella assay and previously published data for all 10 model compounds are summarized in Table III . Considering results from both testing conditions (presence and absence of S9) together, there was 100% concordance (10 of 10) among the five laboratories and the previously published results by NTP (2-6). Seven of the 10 compounds tested were positive either in the TA98-lux and/or TA100-lux in the presence or absence of S9 at all five laboratories. This compound set included: 5N2F, 33DMB, BaP, 14BQD, 2A5N, 2B46dNA and Bus. Three compounds reported negative in the literature with TA98 and TA100 were found non-mutagenic at all five laboratories when tested using both TA98-lux and TA100-lux in the presence or absence of S9. Negative compounds were Anthra, CV and BC. The detailed comparison of individual bioluminescent Salmonella assay results from participating laboratories (strain in the absence or presence of metabolic activation) with previously published data (2-6) revealed 87.5% concordant results (35 of 40). Although the 33DMB was positive in a previously published study with TA98 and, also, in all participating laboratories with TA98-lux in the presence of S9, the compound was also reported positive in TA98 in absence of S9 and TA100 in the presence of S9. Only the Nagoya laboratory (NAG) tested 33DMB as positive in TA100-lux in the presence of S9. In the case of 2B46dNA, there was an agreement among published data with TA98 and all participating laboratories with TA98-lux in the presence and absence of S9. On the other hand, the reported positive data for 2B46dNA in TA100 in the presence and absence of S9 were confirmed with TA100-lux strain only in three out of five laboratories. In the case of 14BQD, there was complete agreement between published TA98 results and data obtained in all participating laboratories with TA98-lux in both the presence and absence of S9. However, the reported positive result in TA100 in the absence of S9 was not reproduced in TA100-lux in any of the participating laboratories.
The individual responses to treatment with model compounds (strain in the absence or presence of metabolic activation) were consistent across participating laboratories providing 92.5% concordant results (37 of 40). The negative compounds (Anthra, BC and CV) did not increase the incidence of revertants at any of the tested concentrations (Figure 1) . Nitrofurazone was positive with all four test conditions at all participating laboratories producing Table III . Inter-laboratory evaluations of the bioluminescent Salmonella reverse mutation assay compared to the NTP for 10 model chemicals
Sites: Participating laboratories: GTN, Groton CT; SDW, Sandwich, Kent, UK; LJ, La Jolla CA; NAG, Nagoya, Japan; CAM, Cambridge, MA. NTP represent data from National Toxicology Program (2-6). Evaluation criteria for positive responses in sites: dose dependent, statistically significant (P 0.05), !2.0-fold increase of revertant colonies over untreated (negative) controls. Evaluation criteria for positive responses in NTP: average of !2.0-fold-increase of revertant colonies over untreated (negative) controls utilizing 1-3 contract labs.
Evaluation of bioluminescent Salmonella assay a characteristic bell shape dose-response curve (Figure 2A) . Consisted with expectations, BaP was positive only with metabolic activation in both strains TA100-lux and TA98-lux ( Figure 2B ). Furthermore, 1,4-benzoquinone and 2A5N ( Figure 2C and 2D, respectively) were positive only with TA98-lux both direct and with metabolic activation and Bus ( Figure 2E ) was positive only with TA100-lux in the presence and absence of metabolic activation. In case of the compounds with discordant results among the participating laboratories, 33DMB with TA100-lux in the presence of S9 produced a weak positive response (,2.5Â) only at NAG laboratory ( Figure 3A) . Furthermore, 2B46dNA yielded a weak positive response with TA100 in the presence of S9 at NAG, LJ and CAM and only one laboratory (NAG) had a weak positive response with TA100-lux in absence of S9 ( Figure 3B ).
Discussion
Previously, we have reported the development of the higher throughput bioluminescent Salmonella reverse mutation assay as a screening tool that could be applied for the prioritization of the compounds in pharmaceutical drug discovery (18) . We have reported a 93-95% concordance of 105 model compounds between the bioluminescent assay and previously published data utilizing the standard Ames assay (18) . Here, we set out to evaluate the robustness, reproducibility and accuracy of the bioluminescent Salmonella assay via inter-laboratory evaluation study. A total of five independent laboratories located on three continents participated in the study. To allow for the gaining of experience of participating laboratories with the assay, the inter-laboratory evaluation study reported here was done 12 months or later after assay implementation on individual locations. To mimic a 'real-life' screening application, the test set of 10 model compounds was evaluated in a sub-set of laboratories in a blinded fashion. We selected 10 model compounds with a range of mutagenic activities. Seven compounds were positive in either, or both strains, and test conditions and three compounds were negative. In addition to evaluating the reproducibility of the data among the participating laboratories, the results were also compared with previously published data (2-6).
The average background incidence of revertants for the TA100-lux strain in the presence or absence of metabolic activation across individual laboratories held steady in the range of 5.2-12.3 revertants per well. In the case of TA98-lux, the background incidence of revertants for the TA98-lux strain in the presence or absence of metabolic activation across laboratories ranged from 1.5 to 2.3. The fact that the previously published background (18) for strains TA100-lux and TA98-lux was 10.1 AE 2.3 and 2.1 AE 1.2, respectively, indicates the stability of our bioluminescent strains. Since the variation in the background frequency within each individual laboratory was a relatively small range (two to three revertants per well), the background frequency likely reflects differences in cell numbers plated. Although the background frequency does not seem to influence the overall interpretation of the data, it is likely that the low background contributed to the weak positive result for 33DMB with TA100-lux in the presence of S9 seen in the NAG laboratory where the negative background ( Table I ) was the smallest (5.9 revertants per plate). Therefore, we recommend keeping the optimal level of background revertants with TA100-lux in the range of 7-15 revertants per plate.
In the case of TA98-lux, the lower background in comparison with TA100-lux reflects the similar ratio as when comparing their parental strains TA100 and TA98. To eliminate the influence of the low background, we used a default 1.5 revertants per well as background for all experiments that where ,1.5. Utilizing this default does not influence the interpretation of the data.
Overall, there was 100% agreement of the compounds (10 of 10) among testing laboratories and previously published data by the NTP (2-6) in the identification of mutagenic compounds. Seven compounds were mutagenic and the other three were non-mutagenic (Table III) . Remarkably, the results of each four testing conditions per compound were almost identical across laboratories as 92.5% were concordant of testing conditions (37 of 40). This clearly indicates that bioluminescent Salmonella assay is an accurate, efficient and robust screening tool across laboratories. When comparing individual experimental results with previously published data by the NTP (2-6), the concordance was 87.5% of testing conditions (35 of 40). These findings are in agreement with our previously published data with 105 compounds (18) . The discrepancies between the NTP and the bioluminescent assay Evaluation of bioluminescent Salmonella assay results are likely to be caused by differences of experimental procedures (i.e. pre-incubation in NTP versus layered protocol in bioluminescent assays and/purity grades in chemicals). In summary, this inter-laboratory evaluation was conducted with five participating laboratories testing 10 model compounds. The results showed an excellent agreement of data across all five participating laboratories. There was 100% agreement of the compounds (10 of 10) in identification of mutagenic compounds among all five inter-laboratory sites and published NTP data. The results of this inter-laboratory evaluation study provide additional evidence that the bioluminescent Salmonella assay is a robust, highly reproducible and accurate mutagenicity screen applicable in early drug discovery. 
